U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H16N2O8
Molecular Weight 304.2533
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOSPAGLUMIC ACID

SMILES

CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

InChIKey=OPVPGKGADVGKTG-BQBZGAKWSA-N
InChI=1S/C11H16N2O8/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1

HIDE SMILES / InChI
ISOSPAGLUMIC ACID is used as an antiallergic agent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.5 µM [Ki]
PubMed

PubMed

TitleDatePubMed
Using proton magnetic resonance imaging and spectroscopy to understand brain "activation".
2007-08
Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor.
2006-12-01
Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
2006-12
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain.
2006-09
Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators.
2006-09
Metabolic analysis of mouse brains that have compromised iron storage.
2006-09
[Alteration of the antinociceptive systems in chronic daily headaches].
2006-08-31
Identifying the affected hemisphere by (1)H-MR spectroscopy in patients with temporal lobe epilepsy and no pathological findings in high resolution MRI.
2006-05
NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat.
2006-05
NAAG peptidase as a therapeutic target: Potential for regulating the link between glucose metabolism and cognition.
2006-04
ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra.
2006-04
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
2006-03-22
Neurotransmitters of the suprachiasmatic nuclei.
2006-02-16
Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes.
2006-02
Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study.
2006-02
N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease.
2006
N-acetylaspartylglutamate (NAAG) in spinal cord injury and disease.
2006
Synthesis of N-acetylaspartyl-glutamate (NAAG) and N-acetylaspartate (NAA) in axons and glia of the crayfish medial giant nerve fiber.
2006
Functions of N-acetylaspartate and N-acetylaspartylglutamate in brain: evidence of a role in maintenance of higher brain integrative activities of information processing and cognition.
2006
Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system.
2006
A brief overview of N-acetylaspartate and N-acetylaspartylglutamate.
2006
NAAG peptidase inhibitors and their potential for diagnosis and therapy.
2005-12
Optimized diffusion-weighted spectroscopy for measuring brain glutamate apparent diffusion coefficient on a whole-body MR system.
2005-12
Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia.
2005-12
Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism.
2005-11
Neonatal administration of N-acetyl-L-aspartyl-L-glutamate induces early neurodegeneration in hippocampus and alters behaviour in young adult rats.
2005-10-15
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
2005-10
Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination.
2005-09-13
Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.
2005-09
The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia.
2005-09
The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats.
2005-09
Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2.
2005-08
Strategies to increase central N-acetyl aspartylglutamate: a potential treatment for schizophrenia and bipolar disorders.
2005-07-15
Effect of N-acetylaspartylglutamate (NAAG) on non-quantal and spontaneous quantal release of acetylcholine at the neuromuscular synapse of rat.
2005-07
Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy.
2005-05
Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
2005-05
Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand.
2005-03-16
Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain.
2005-03-01
In vitro 1H NMR spectroscopy shows an increase in N-acetylaspartylglutamate and glutamine content in the hippocampus of amygdaloid-kindled rats.
2005-03
High-field localized 1H NMR spectroscopy in the anesthetized and in the awake monkey.
2004-12
Serotonin1B receptors: from protein to physiological function and behavior.
2004-10
Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility.
2004-09
Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
2004-08-06
Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia.
2004-08
Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model.
2004-07
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
2004-06
Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF.
2004-05-11
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.
2004-05
The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
2004-05
Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3.
2004-04
Patents

Patents

Name Type Language
ZY 15106
Preferred Name English
ISOSPAGLUMIC ACID
INN   MART.   WHO-DD  
INN  
Official Name English
ISOSPAGLUMIC ACID [MART.]
Common Name English
ZY-15106
Code English
NAAGA
Common Name English
NAAG
Common Name English
isospaglumic acid [INN]
Common Name English
N-ACETYLASPARTYLGLUTAMIC ACID
Common Name English
Isospaglumic acid [WHO-DD]
Common Name English
N-(N-ACETYL-L-.ALPHA.-ASPARTYL)-L-GLUTAMIC ACID
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29714
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
Code System Code Type Description
RXCUI
236303
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY RxNorm
INN
5595
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL1329032
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
WIKIPEDIA
N-Acetylaspartylglutamic acid
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
CHEBI
73688
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID3091535
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
PUBCHEM
188803
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
CAS
3106-85-2
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
FDA UNII
1W8M12WXYL
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
EVMPD
SUB08337MIG
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
NCI_THESAURUS
C83847
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY
SMS_ID
100000093105
Created by admin on Mon Mar 31 18:16:31 GMT 2025 , Edited by admin on Mon Mar 31 18:16:31 GMT 2025
PRIMARY